Journal for ImmunoTherapy of Cancer: 11 (5)

Basic tumor immunology

Original research: Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors (25 May, 2023)
Clémence Demerlé, Laurent Gorvel, Marielle Mello, Sonia Pastor, Clara Degos, Ana Zarubica, Fabien Angelis, Frédéric Fiore, Jacques A Nunes, Bernard Malissen, Laurent Greillier, Geoffrey Guittard, Hervé Luche, Fabrice Barlesi, Daniel Olive
Original research: Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity (19 May, 2023)
Laura Fernandez-Rodriguez, Chiara Cianciaruso, Ruben Bill, Marcel P Trefny, Richard Klar, Nicole Kirchhammer, Mélanie Buchi, Julia Festag, Sven Michel, Rainer H Kohler, Elham Jones, Andre Maaske, Johannes vom Berg, Sebastian Kobold, Abhishek S Kashyap, Frank Jaschinski, Karen O Dixon, Mikael J Pittet, Alfred Zippelius
Original research: Dual receptor T cells mediate effective antitumor immune responses via increased recognition of tumor antigens (15 May, 2023)
Hyun J Jang, Christine Caron, Calvin K Lee, Lu Wang, Burhan Jama, Jack D Bui, Gerald P Morris
Original research: AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells (10 May, 2023)
Ganggang Zhang, Bin Lan, Xin Zhang, Mengyao Lin, Yi Liu, Junsong Chen, Fang Guo
Original research: Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment (5 May, 2023)
Pengfei Xu, Joy C Yang, Bo Chen, Christopher Nip, Jonathan E Van Dyke, Xiong Zhang, Hong-Wu Chen, Christopher P Evans, William J Murphy, Chengfei Liu
Original research: Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression (5 May, 2023)
Veronica Finisguerra, Tereza Dvorakova, Matteo Formenti, Pierre Van Meerbeeck, Lionel Mignion, Bernard Gallez, Benoit J Van den Eynde

Case report

Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report (23 May, 2023)
Darien E Reed-Perino, Michael Lai, Evan Y Yu, Michael T Schweizer
Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade (8 May, 2023)
Luke Frankiw, Arun Singh, Cole Peters, Begoña Comin-Anduix, Beata Berent-Maoz, Mignonette Macabali, Kiana Shammaie, Crystal Quiros, Paula Kaplan-Lefko, Ignacio Baselga Carretero, Antoni Ribas, Theodore Scott Nowicki
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma (3 May, 2023)
Sharmila Raghunandan, Melinda Pauly, William G Blum, Muna Qayed, Madhav V Dhodapkar, Mohamed Elkhalifa, Benjamin Watkins, Michelle Schoettler, Edwin Horwitz, Suhag Parikh, Shanmuganathan Chandrakasan, Kathryn Leung, Elyse Bryson, Laura Deeb, Jonathan L Kaufman, Diana Worthington-White, Adina Alazraki, Jordan M Schecter, Deepu Madduri, Carolyn C Jackson, Enrique Zudaire, Agne Taraseviciute-Morris, Alexander Babich, Tonia Nesheiwat, Martin Vogel, Nikoletta Lendvai, Lida Pacaud, Kirsten M Williams

Clinical/translational cancer immunotherapy

Original research: Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series (31 May, 2023)
Cyrille Coustal, Juliette Vanoverschelde, Xavier Quantin, Candice Lesage, Jean-Marie Michot, Ariane Lappara, Stephane Ederhy, Eric Assenat, Maxime Faure, Nahema Issa, Olivier Lambotte, Mathieu Puyade, Olivier Dereure, Diego Tosi, Patricia Rullier, Isabelle Serre, Romaric Larcher, Kada Klouche, Gérald Chanques, Hélène Vernhet-Kovacsik, Jean-Luc Faillie, Audrey Agullo, François Roubille, Philippe Guilpain, Alexandre Thibault Jacques Maria
Original research: First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma (26 May, 2023)
Julius Strauss, Jean-Laurent Deville, Mario Sznol, Alain Ravaud, Marco Maruzzo, Russell K Pachynski, Theodore S Gourdin, Michele Maio, Luc Dirix, Jeffrey Schlom, Renee N Donahue, Yo-Ting Tsai, XiaoZhe Wang, Yulia Vugmeyster, Frank Beier, Joerg Seebeck, Andreas Schroeder, Sarah Chennoufi, James L Gulley
Original research: Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses (25 May, 2023)
Amrendra Kumar, Vijay Ramani, Vijaya Bharti, Daniel de Lima Bellan, Nabil Saleh, Roman Uzhachenko, Chengli Shen, Carlos Arteaga, Ann Richmond, Sangeetha M Reddy, Anna Vilgelm
Original research: Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab (22 May, 2023)
Cathrine Lund Lorentzen, Julie Westerlin Kjeldsen, Eva Ehrnrooth, Mads Hald Andersen, Inge Marie Svane
Original research: Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma (19 May, 2023)
Florian Märkl, Mohamed-Reda Benmebarek, Julius Keyl, Bruno L Cadilha, Martina Geiger, Clara Karches, Hannah Obeck, Melanie Schwerdtfeger, Stefanos Michaelides, Daria Briukhovetska, Sophia Stock, Jakob Jobst, Philipp Jie Müller, Lina Majed, Matthias Seifert, Anna-Kristina Klüver, Theo Lorenzini, Ruth Grünmeier, Moritz Thomas, Adrian Gottschlich, Richard Klaus, Carsten Marr, Michael von Bergwelt-Baildon, Simon Rothenfusser, Mitchell P Levesque, Markus Vincent Heppt, Stefan Endres, Christian Klein, Sebastian Kobold
Original research: CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models (4 May, 2023)
Jian Ye, Nicholas W Gavras, David C Keeley, Angela L Hughson, Gary Hannon, Tara G Vrooman, Maggie L Lesch, Carl J Johnston, Edith M Lord, Brian A Belt, David C Linehan, Jim Eyles, Scott A Gerber
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial (4 May, 2023)
Jason A Chesney, Igor Puzanov, Frances A Collichio, Parminder Singh, Mohammed M Milhem, John Glaspy, Omid Hamid, Merrick Ross, Philip Friedlander, Claus Garbe, Theodore Logan, Axel Hauschild, Celeste Lebbé, Harshada Joshi, Wendy Snyder, Janice M Mehnert

Immunotherapy biomarkers

Original research: Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors (31 May, 2023)
Julia-Christina Stadler, Laura Keller, Christian Mess, Alexander T Bauer, Julian Koett, Glenn Geidel, Isabel Heidrich, Sabine Vidal-y-Sy, Antje Andreas, Carlotta Stramaglia, Mark Sementsov, Wiebcke Haberstroh, Benjamin Deitert, Inka Lilott Hoehne, Robin Reschke, Thomas Haalck, Klaus Pantel, Christoffer Gebhardt, Stefan W Schneider
Original research:
CD71⁺ erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors
(26 May, 2023)
Najmeh Bozorgmehr, Isobel Okoye, Siavash Mashhouri, Julia Lu, Petya Koleva, John Walker, Shokrollah Elahi
Original research: The NR_109/FUBP1/c-Myc axis regulates TAM polarization and remodels the tumor microenvironment to promote cancer development (22 May, 2023)
Cong Zhang, Sisi Wei, Suli Dai, Xiaoya Li, Huixia Wang, Hongtao Zhang, Guogui Sun, Baoen Shan, Lianmei Zhao
Original research: Radiomic and clinical data integration using machine learning predict the efficacy of anti-PD-1 antibodies-based combinational treatment in advanced breast cancer: a multicentered study (22 May, 2023)
Jianli Zhao, Zhixian Sun, Yunfang Yu, Zhongyu Yuan, Ying Lin, Yujie Tan, Xiaohui Duan, Herui Yao, Ying Wang, Jieqiong Liu
Original research: Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trial (19 May, 2023)
Axel Stenmark Tullberg, Martin Sjöström, Lena Tran, Emma Niméus, Fredrika Killander, Anikó Kovács, Dan Lundstedt, Erik Holmberg, Per Karlsson
Original research: Cross-cohort analysis identified an immune checkpoint-based signature to predict the clinical outcomes of neuroblastoma (2 May, 2023)
Liang Zeng, Hui Xu, Shu-Hua Li, Shuo-Yu Xu, Kai Chen, Liang-Jun Qin, Lei Miao, Fang Wang, Ling Deng, Feng-Hua Wang, Le Li, Sha Fu, Na Liu, Ran Wang, Ying-Qing Li, Hai-Yun Wang

Immune cell therapies and immune cell engineering

Original research: Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model (31 May, 2023)
Diana Rose E Ranoa, Preeti Sharma, Claire P Schane, Amber N Lewis, Edward Valdez, Venkata V V R Marada, Marlies V Hager, Will Montgomery, Steven P Wolf, Karin Schreiber, Hans Schreiber, Keith Bailey, Timothy M Fan, Paul J Hergenrother, Edward J Roy, David M Kranz
Original research:
Cell surface marker-based capture of neoantigen-reactive CD8⁺ T-cell receptors from metastatic tumor digests
(31 May, 2023)
Praveen D Chatani, Frank J Lowery, Neilesh B Parikh, Kyle J Hitscherich, Rami Yossef, Victoria Hill, Jared J Gartner, Biman Paria, Maria Florentin, Satyajit Ray, Alakesh Bera, Maria Parkhust, Paul Robbins, Sri Krishna, Steven A Rosenberg
Original research: Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia (22 May, 2023)
Anil Kumar, Adeleh Taghi Khani, Caroline Duault, Soraya Aramburo, Ashly Sanchez Ortiz, Sung June Lee, Anthony Chan, Tinisha McDonald, Min Huang, Norman J. Lacayo, Kathleen M. Sakamoto, Jianhua Yu, Christian Hurtz, Martin Carroll, Sarah K. Tasian, Lucy Ghoda, Guido Marcucci, Zhaohui Gu, Steven T. Rosen, Saro Armenian, Shai Izraeli, Chun-Wei Chen, Michael A. Caligiuri, Stephen J. Forman, Holden T. Maecker, Srividya Swaminathan
CAR T-cell detection scoping review: an essential biomarker in critical need of standardization (22 May, 2023)
David P Turicek, Victoria M Giordani, Josquin Moraly, Naomi Taylor, Nirali N Shah

Oncolytic and local immunotherapy

Original research:
Nasal administration of recombinant Neospora caninum secreting IL-15/IL-15Rα inhibits metastatic melanoma development in lung
(16 May, 2023)
Arthur Battistoni, Louis Lantier, Anne di Tommaso, Céline Ducournau, Laurie Lajoie, Mahtab Samimi, Loïs Coënon, Clément Rivière, Mathieu Epardaud, Leslie Hertereau, Agathe Poupée-Beaugé, Juliette Rieu, Marie-Noëlle Mévélec, Gordon Scott Lee, Nathalie Moiré, Stephanie Germon, Isabelle Dimier-Poisson
Original research: Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis (16 May, 2023)
Duo Wang, Guanhua Qiu, Xiaoqi Zhu, Qin Wang, Chunyan Zhu, Chao Fang, Junjie Liu, Kun Zhang, Yan Liu
Original research: Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial (12 May, 2023)
Mikail Gögenur, Lukas Balsevicius, Mustafa Bulut, Nesibe Colak, Tobias Freyberg Justesen, Anne-Marie Kanstrup Fiehn, Marianne Bøgevang Jensen, Kathrine Høst-Rasmussen, Britt Cappelen, Shruti Gaggar, Asma Tajik, Jawad Ahmad Zahid, Astrid Louise Bjørn Bennedsen, Tommaso Del Buono D’Ondes, Hans Raskov, Susanne Gjørup Sækmose, Lasse Bremholm Hansen, Ali Salanti, Susanne Brix, Ismail Gögenur
Original research:
OncoVEX^mGM-CSFexpands tumor antigen-specific CD8+ T-cell response in preclinical models
(10 May, 2023)
Juan Estrada, Jinghui Zhan, Petia Mitchell, Jonathan Werner, Pedro J Beltran, Jason DeVoss, Jing Qing, Keegan S Cooke

Position article and guidelines

Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs (3 May, 2023)
Tian Zhang, Patrick M Forde, Ryan J Sullivan, Elad Sharon, Elizabeth Barksdale, Wendy Selig, Scot Ebbinghaus, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc S Hurlbert, Mark Stewart, Michael B Atkins

Review

Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies (23 May, 2023)
Luc Magré, Monique M A Verstegen, Sonja Buschow, Luc J W van der Laan, Maikel Peppelenbosch, Jyaysi Desai
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets (22 May, 2023)
Vladimir Laletin, Pierre-Louis Bernard, Cathy Costa da Silva, Geoffrey Guittard, Jacques A Nunes

Main menu

Table of contents

May 2023 - Volume 11 - 5

Basic tumor immunology

Case report

Clinical/translational cancer immunotherapy

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Oncolytic and local immunotherapy

Position article and guidelines

Review

Correction

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

May 2023 - Volume 11 - 5

Basic tumor immunology

Case report

Clinical/translational cancer immunotherapy

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Oncolytic and local immunotherapy

Position article and guidelines

Review

Correction